Agne Krilaviciute, Rudolf Kaaks, Petra Seibold, Maxime de Vrieze, Jale Lakes, Jan Philipp Radtke, Markus Kuczyk, Nina N Harke, Jürgen Debus, Christoph A Fink, Kathleen Herkommer, Jürgen E Gschwend, Valentin H Meissner, Axel Benner, Glen Kristiansen, Boris Hadaschik, Christian Arsov, Lars Schimmöller, Gerald Antoch, Frederik L Giesel, Marcus Makowski, Frank Wacker, Heinz-Peter Schlemmer, Nikolaus Becker, Peter Albers
BACKGROUND: Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr. OBJECTIVE: To identify men at age 45 yr with a low risk of PCa. DESIGN, SETTING, AND PARTICIPANTS: A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE)...
May 15, 2024: European Urology